KOL Views: Benchmarking Tecentriq's top-line success in neoadjuvant TNBC

The battle for market share in triple-negative breast cancer (TNBC) remains a closely run affair. Results from the Phase III Keynote-522 trial gave Merck & Co.'s Keytruda (pembrolizumab) an advantage thanks to a modest improvement in pathological complete response (pCR), but Roche could be set to wrestle momentum back thanks to newly revealed top-line results from the Phase III IMpassion031 study of Tecentriq (atezolizumab).

To provide FirstWord readers with rapid feedback on the evolving landscape for immuno-oncology (I/O) drugs as neoadjuvant and adjuvant therapy for TNBC, we are hosting an expert call with a key opinion leader (KOL) next week.

Key topics that will be discussed during the call include, among other things… how has use of PD-(L)1 inhibitors to treat TNBC evolved over time in the neoadjuvant, adjuvant and metastatic settings; prior to the IMpassion031 readout, how did Tecentriq and Keytruda appear to stack up relative to one another; is there any reason to suspect a difference between the two drugs and/or the PD-1 and PD-L1 inhibitor mechanisms in TNBC; in the neoadjuvant setting, how impressive was Keytruda's performance in Keynote-522 where it improved pCR by 13.6% when added to chemotherapy (64.8% vs 51.2%) and demonstrated a positive trend on event-free survival (EFS); how do initial IMpassion031 findings compare to available Keynote-522 data; how, if at all, will the recent Impassion031 readout impact prescribing patterns in TNBC; when detailed results are made available, how much of a pCR advantage would be impressive enough to really catch your eye and how confident are you that Tecentriq can achieve that; what amount of EFS benefit are you hoping to see from the Keynote-522 and Impassion031 trials; if one drug or the other demonstrated a modestly strong profile in the neoadjuvant setting, would this be sufficient to secure a larger market share in the adjuvant setting; is there any reason to doubt that pCR data in the absence of a significant EFS benefit will be enough to support approval from the FDA for an I/O drug in TNBC; and what readouts in TNBC are you most looking forward to as potentially practice-changing?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the use of anti-PD-(L)1 mAbs in TNBC.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.